In this phase I trial, Lai and colleagues evaluated the safety and toxicity of EGFR antisense DNA therapy in 20 patients with advanced squamous-cell carcinoma of the head and neck. All patients ...

Researchers at Tokyo University of Science have developed Chol-HDOs, which efficiently penetrate the brain, overcoming ...

Getting therapeutic drugs past the blood-brain barrier has long been one of medicine's most difficult challenges, limiting ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531, has met all trial endpoints, showing the drug ...

Scientists use short oligonucleotides as primers for polymerase chain reaction and next-generation sequencing, in DNA microarrays and fluorescence in situ hybridization, and in antisense therapies. (1 ...

The immunomodulatory character of bacterial CpG DNA is well known ... they explained the immunostimulatory properties of certain antisense oligonucleotides, which had not fit into any prevailing ...

These informational drugs, known as antisense therapies, chemically modify genetic sequences to reach specific targets and block disease-associated mRNA. Agrawal likens these therapies to “genetic ...

Among the DNA repair genes identified ... These neurons were then treated with an antisense oligonucleotide (ASO) that binds to MSH3 mRNA, reducing its expression, and changes in CAG repeat ...

An antisense drug in development at GSK has shown ... reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection in people ...

RNA epigenetic modifications have uncovered as not only an intermediary structure between DNA and protein or an effector ...